Endo Pharmaceuticals Recent News
Piper Jaffray Reiterates Neutral Rating, $44 PT on Endo Pharmaceuticals
J.P. Morgan Resumes Coverage of Endo Pharmaceuticals with Overweight and PT of $50
Citi Raises Endo Pharmaceuticals Estimates
Citi Comments On Endo Pharmaceuticals Price Target
Oppenheimer Comments On Endo Pharmaceuticals 1Q11 Results
Citigroup Raises PT On Endo Pharmaceuticals To $48
Stifel Nicolaus Summary
UPDATE: Oppenheimer Raises PT on Endo Pharmaceuticals to $48 (ENDP)
Oppenheimer Raises PT On Endo Pharmaceuticals To $48
Jefferies Maintains Buy on Endo Pharmaceuticals (ENDP)
Piper Jaffray Raises PT On Endo Pharmaceuticals To $40
JP Morgan On Endo Pharmaceuticals
Oppenheimer Maintains ENDP Rating, Estimates And PT
Goldman Sachs Analyzes Fortesta Gel Approval (ENDP)
Endo Pharmaceuticals Portfolio Should Benefit from Qualitest Acquisition (ENDP)
J.P. Morgan Resumes Coverage on Endo Pharmaceuticals (ENDP)
FDA Cancels Opana TR Panel, No Generics = No Risk For Endo
Endo Pharmaceuticals Focusing On Execution
Citigroup Releases Endo Pharmaceuticals Core Product Trends; Explains Price Target
Buy Rating For AAPL, ENDP